Knopp is directing its potassium channel activator program to preclinical and clinical development of small-molecule drug candidates against a validated, anti-seizure pharmaceutical target encoded by the KCNQ2 gene.
Il premio sostiene lo sviluppo preclinico e clinico da parte di Knopp di candidati farmaci a piccole molecole dirette a un target farmaceutico anti-epilettico approvato noto come Kv7.